Advertisement
Canada markets closed
  • S&P/TSX

    22,851.17
    -144.22 (-0.63%)
     
  • S&P 500

    5,588.27
    -78.93 (-1.39%)
     
  • DOW

    41,198.08
    +243.60 (+0.59%)
     
  • CAD/USD

    0.7305
    -0.0010 (-0.13%)
     
  • CRUDE OIL

    82.89
    +2.13 (+2.64%)
     
  • Bitcoin CAD

    88,402.85
    -787.03 (-0.88%)
     
  • CMC Crypto 200

    1,342.06
    -0.26 (-0.02%)
     
  • GOLD FUTURES

    2,462.50
    -5.30 (-0.21%)
     
  • RUSSELL 2000

    2,242.06
    -21.61 (-0.95%)
     
  • 10-Yr Bond

    4.1460
    -0.0210 (-0.50%)
     
  • NASDAQ

    17,996.92
    -512.42 (-2.77%)
     
  • VOLATILITY

    14.45
    +1.26 (+9.58%)
     
  • FTSE

    8,187.46
    +22.56 (+0.28%)
     
  • NIKKEI 225

    41,097.69
    -177.39 (-0.43%)
     
  • CAD/EUR

    0.6678
    -0.0030 (-0.45%)
     

One AstraZeneca Insider Raised Stake By 50% In Previous Year

Viewing insider transactions for AstraZeneca PLC's (LON:AZN ) over the last year, we see that insiders were net buyers. This means that a larger number of shares were purchased by insiders in relation to shares sold.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

Check out our latest analysis for AstraZeneca

AstraZeneca Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Independent Chairman Michel Demare bought UK£203k worth of shares at a price of UK£102 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of UK£124. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

ADVERTISEMENT

The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 0.03% of AstraZeneca shares, worth about UK£54m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At AstraZeneca Tell Us?

The fact that there have been no AstraZeneca insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in AstraZeneca and we see no evidence to suggest they are worried about the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing AstraZeneca. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of AstraZeneca.

Of course AstraZeneca may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com